HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.

AbstractBACKGROUND:
Identifying pretreatment blood markers that distinguish prognostic groups of patients with advanced pancreatic ductal adenocarcinoma (PDAC) under first-line FOLFIRINOX chemotherapy has the potential to improve management of this condition. Aim of this study was to determine the prognostic utility of a range of pretreatment, inflammation-related, blood cell markers in this group of patients.
MATERIAL AND METHODS:
Data from a training cohort were analyzed to identify potential pretreatment blood markers correlating to survival outcomes. The most informative markers were further analyzed in a validation cohort comprised patients from a geographically separate cancer center undergoing the same treatment.
RESULTS:
A total of 138 consecutive patients receiving FOLFIRINOX chemotherapy between 2010 and 2019, constituted the training cohort. Neutrophil/lymphocyte (NLR), monocyte/lymphocyte (MLR), and platelet/lymphocyte ratio (PLR) as well as the systemic inflammatory response index (SIRI) and CA19.9 showed prognostic significance in addition to tumor stage. A pretreatment SIRI score cutoff of 2.35 differentiated between a poor prognostic group with median overall survival (mOS) 5.1 months and a better prognostic group, mOS 12.5 months. SIRI ≤/> 2.35 was predictive of mOS in patients with locally advanced and metastatic PDAC. SIRI was confirmed as a prognostic marker in a validation cohort of 67 patients with mOS of 13.4 months and 6.3 months for those with SIRI ≤ 2.35 and >2.35, respectively. Additional analysis revealed baseline SIRI as being prognostic within additional subgroups of patients in both cohorts.
CONCLUSIONS:
This large, retrospective, analysis of real-world patients receiving first-line FOLFIRINOX chemotherapy for advanced PDAC has identified the pretreatment blood SIRI as a strong prognostic marker for survival. This will allow better counseling of patients with regards to the benefits of treatment, improved stratification within clinical trials, and potentially identify groups of patients for novel therapy trials as first-line treatment.
AuthorsKonstantinos Kamposioras, George Papaxoinis, Mohamed Dawood, Jordan Appleyard, Fiona Collinson, Angela Lamarca, Usman Ahmad, Richard A Hubner, Francesca Wright, Rille Pihlak, Iva Damyanova, Bilal Razzaq, Juan W Valle, Mairéad G McNamara, Alan Anthoney
JournalActa oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 61 Issue 5 Pg. 583-590 (May 2022) ISSN: 1651-226X [Electronic] England
PMID35392758 (Publication Type: Journal Article)
Chemical References
  • Biomarkers
  • folfirinox
  • Oxaliplatin
  • Irinotecan
  • Leucovorin
  • Fluorouracil
Topics
  • Adenocarcinoma (drug therapy)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Biomarkers
  • Fluorouracil
  • Humans
  • Inflammation (pathology)
  • Irinotecan
  • Leucovorin
  • Oxaliplatin
  • Pancreatic Neoplasms (drug therapy)
  • Prognosis
  • Retrospective Studies
  • Pancreatic Neoplasms

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: